Home > Insider Trading > Filing (0001415889-25-007039)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1127537	Pulmonx Corp	LUNG	Surgical & Medical Instruments & Apparatus (3841)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1354228	Aaron David Lehman	C/O Pulmonx Corporation 700 Chesapeake Drive Redwood City CA 94063	General Counsel	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2025-03-03	669	$7.14	197,182	No	4	S	Direct
Common Stock	Disposition	2025-03-03	1,177	$7.14	196,005	No	4	S	Direct
Common Stock	Disposition	2025-03-03	4,490	$7.14	191,515	No	4	S	Direct
Common Stock	Disposition	2025-03-03	2,397	$7.14	189,118	No	4	S	Direct
Common Stock	Disposition	2025-03-03	13,622	$7.97	175,496	No	4	S	Direct
Common Stock	Acquisiton	2025-03-03	108,000	$0.00	283,496	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct

Footnotes

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021.
These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022.
These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.88 to $8.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025.